/ /

  • linkedin
  • Increase Font
  • Sharebar

    The CEO that nobody loves

     

    Even his ex-girl friend, Katie, got in on the act. She posted conversations between herself (with her last name redacted) and the man of the hour from her FaceBook page purporting to show Shkreli offering her money in exchange for sex. Embarrassing. One may suspect, it appears, that the bloom is off the rose when it comes to that once amorous relationship. Never heard of Snapchat, Shkreli?

    Candidates for the U.S. Presidency, who have never met the man, lined up to announce that they hate his guts. Only his mother, it seems, has yet to go public with her disdain for this CEO of a small pharmaceutical company. 

    What did this man do to engender such widespread repudiation? He is the opportunist, of course, who bought the only firm licensed by the FDA to manufacture and market the drug, pyrimethamine (Daraprim), and promptly raised the price from $13.50 per dose to $750. Widely described in the press as a drug for AIDS patients, we ophthalmologists are of course very familiar with this as a therapy for toxoplasma retinochoroiditis.

    Peter McDonnell, MD
    He is director of The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, and chief medical editor of ...

    New Call-to-action

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • Remy JayRemy Jay
      123

    Poll

    View Results